SEHK Growth Companies With High Insider Ownership And Up To 95% Earnings Growth

Amid fluctuating global markets, with the Hang Seng Index showing a notable rise last week, investors are keenly observing trends and opportunities in Hong Kong's vibrant economy. In this context, growth companies with high insider ownership present a compelling narrative, as such firms often signal strong confidence from those closest to the business in its prospects and governance.

Top 10 Growth Companies With High Insider Ownership In Hong Kong

Name	Insider Ownership	Earnings Growth
iDreamSky Technology Holdings (SEHK:1119)	20.1%	104.1%
Fenbi (SEHK:2469)	32.2%	43%
DPC Dash (SEHK:1405)	38.2%	89.7%
Zylox-Tonbridge Medical Technology (SEHK:2190)	18.5%	79.3%
Adicon Holdings (SEHK:9860)	22.3%	29.6%
Tian Tu Capital (SEHK:1973)	34%	70.5%
RemeGen (SEHK:9995)	12.2%	54.9%
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)	13.9%	100.1%
Zhejiang Leapmotor Technology (SEHK:9863)	15%	75.4%
Beijing Airdoc Technology (SEHK:2251)	27.7%	83.9%

Click here to see the full list of 51 stocks from our Fast Growing SEHK Companies With High Insider Ownership screener.

Let's review some notable picks from our screened stocks.

Dongyue Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Dongyue Group Limited operates as an investment holding company that manufactures and distributes polymers, organic silicone, refrigerants, and other chemical products primarily in the People's Republic of China and globally, with a market capitalization of approximately HK$14.80 billion.

Operations: Dongyue Group's revenue is generated from polymers (CN¥4.55 billion), refrigerants (CN¥5.48 billion), organic silicone (CN¥4.86 billion), and dichloromethane PVC and liquid alkali (CN¥1.21 billion).

Insider Ownership: 15.4%

Earnings Growth Forecast: 35.7% p.a.

Dongyue Group, a Hong Kong-based company, exhibits mixed financial dynamics with a significant decline in net profit margins from 19.3% to 4.9% year-over-year and a substantial decrease in annual net income by approximately 82%. Despite these challenges, the company is expected to see robust earnings growth at an annual rate of 35.7%, outpacing the local market's average. This growth is underpinned by anticipated revenue increases of 15.4% annually, also above market trends. Recent executive changes and dividend reductions reflect ongoing adjustments within the company's leadership and financial strategy.

• Navigate through the intricacies of Dongyue Group with our comprehensive analyst estimates report here.

• Upon reviewing our latest valuation report, Dongyue Group's share price might be too optimistic.

SEHK:189 Earnings and Revenue Growth as at Jun 2024

Beijing Fourth Paradigm Technology

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Beijing Fourth Paradigm Technology Co., Ltd. is an investment holding company that offers platform-centric artificial intelligence solutions in the People's Republic of China, with a market capitalization of approximately HK$25.10 billion.

Operations: The company's revenue is derived from three primary segments: the Sage AI Platform generating CN¥2.51 billion, SageGPT AIGS Services contributing CN¥415.50 million, and Shift Intelligent Solutions at CN¥1.28 billion.

Insider Ownership: 22.8%

Earnings Growth Forecast: 96% p.a.

Beijing Fourth Paradigm Technology, despite a low forecasted Return on Equity of 6% in three years, is positioned for notable growth with earnings expected to increase significantly. The company recently initiated a share repurchase program, enhancing shareholder value by potentially increasing net asset value and earnings per share. Revenue growth at 19.3% annually surpasses Hong Kong's average (7.8%), though it trails the high-growth benchmark of 20%. No insider trading was reported in the past three months.

• Click to explore a detailed breakdown of our findings in Beijing Fourth Paradigm Technology's earnings growth report.

• According our valuation report, there's an indication that Beijing Fourth Paradigm Technology's share price might be on the expensive side.

SEHK:6682 Earnings and Revenue Growth as at Jun 2024

RemeGen

Simply Wall St Growth Rating: ★★★★★☆

Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on developing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States, with a market capitalization of approximately HK$22.84 billion.

Operations: The company generates revenue primarily from its biopharmaceutical research, service, production, and sales segment, totaling CN¥1.25 billion.

Insider Ownership: 12.2%

Earnings Growth Forecast: 54.9% p.a.

RemeGen, despite its current unprofitability with a net loss of CNY 348.92 million in Q1 2024, is poised for significant growth. Its revenue has nearly doubled to CNY 330.43 million from the previous year, and earnings are expected to grow by 54.91% annually. The company's recent activities, including securing FDA fast track designation for telitacicept and proposing substantial amendments to its bylaws, underscore its strategic initiatives aimed at rapid development and market readiness.

• Dive into the specifics of RemeGen here with our thorough growth forecast report.

• The analysis detailed in our RemeGen valuation report hints at an deflated share price compared to its estimated value.

SEHK:9995 Earnings and Revenue Growth as at Jun 2024

Next Steps

• Access the full spectrum of 51 Fast Growing SEHK Companies With High Insider Ownership by clicking on this link.

• Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:189 SEHK:6682 and SEHK:9995.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com